Table 2:
Cohort characteristics—screened positive vs negative for hyperaldosteronism
| Characteristics | Screened | Positive Screen | Negative Screen | p value |
|---|---|---|---|---|
| (N = 1977) | (N = 727) | (N = 1250) | ||
| Age at index, mean (SD) | 64.9 (12.51) | 63.6 (11.45) | 65.6 (13.04) | < 0.0001 |
| Female, n (%) | 1035 (52.4%) | 357 (49.1%) | 678 (54.2%) | 0.028 |
| Race | < 0.0001 | |||
| White, n (%) | 742 (37.5%) | 236 (32.5%) | 506 (40.5%) | |
| Black, n (%) | 549 (27.8%) | 243 (33.4%) | 306 (24.5%) | |
| Hispanic, n (%) | 440 (22.3%) | 160 (22.0%) | 280 (22.4%) | |
| Asian and Pacific Islander, n (%) | 210 (10.6%) | 70 (9.6%) | 140 (11.2%) | |
| American Indian and Alaska Native, n (%) | 2 (0.1%) | 1 (0.1%) | 1 (0.1%) | |
| Other/Unknown, n (%) | 34 (1.7%) | 17 (2.3%) | 17 (1.4%) | |
| SBP, mean (SD) | 134.3 (17.11) | 135.2 (16.85) | 133.9 (17.25) | 0.198 |
| DBP, mean (SD) | 73.4 (13.28) | 75.6 (12.73) | 72.0 (13.43) | < 0.0001 |
| BMI ≥ 30, n (%) | 1041 (53.6%) | 396 (55.5%) | 645 (52.5%) | 0.211 |
| Smoking status | < 0.0001 | |||
| Current smoker, n (%) | 58 (2.9%) | 22 (3.0%) | 36 (2.9%) | |
| Former smoker, n (%) | 669 (33.8%) | 211 (29.0%) | 458 (36.6%) | |
| Missing, n (%) | 121 (6.1%) | 37 (5.1%) | 84 (6.7%) | |
| Never, n (%) | 1129 (57.1%) | 457 (62.9%) | 672 (53.8%) | |
| Comorbidities | ||||
| Ischemic heart disease, n (%) | 37 (1.9%) | 11 (1.5%) | 26 (2.1%) | 0.370 |
| CHF, n (%) | 123 (6.2%) | 33 (4.5%) | 90 (7.2%) | 0.018 |
| Cerebrovascular disease, n (%) | 28 (1.4%) | 10 (1.4%) | 18 (1.4%) | 0.907 |
| Dementia, n (%) | 8 (0.4%) | 1 (0.1%) | 7 (0.6%) | 0.154 |
| Chronic kidney disease, n (%) | 497 (26.2%) | 135 (19.6%) | 362 (30.0%) | < 0.0001 |
| Peripheral artery disease, n (%) | 54 (2.7%) | 10 (1.4%) | 44 (3.5%) | 0.005 |
| Sleep apnea, n (%) | 231 (11.7%) | 92 (12.7%) | 139 (11.1%) | 0.306 |
| Diabetes mellitus, n (%) | 856 (43.3%) | 283 (38.9%) | 573 (45.8%) | 0.003 |
| Laboratory | ||||
| Aldosterone, mean (SD) | 12.8 (15.29) | 17.9 (20.06) | 9.7 (10.28) | < 0.0001 |
| Renin, mean (SD) | 3.2 (8.15) | 0.3 (0.32) | 4.9 (9.94) | < 0.0001 |
| Sodium, mean (SD) | 138.6 (3.26) | 139.0 (3.14) | 138.4 (3.31) | < 0.0001 |
| Bicarbonate, mean (SD) | 27.4 (3.08) | 27.9 (2.92) | 27.1 (3.12) | < 0.0001 |
| Potassium, mean (SD) | 4.0 (0.54) | 3.9 (0.52) | 4.1 (0.55) | < 0.0001 |
| Creatinine, mean (SD) | 1.3 (1.08) | 1.2 (0.88) | 1.4 (1.18) | 0.001 |
| MRA usage, n (%) | 445 (22.5%) | 227 (31.2%) | 218 (17.4%) | < 0.0001 |
BMI, body mass index; CHF, congestive heart failure; DBP, diastolic blood pressure; MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; SD, standard deviation.